ST-elevation acute coronary syndrome with thrombotic occlusion of the proximal segment of the circumflex artery in a patient with antiphospholipid syndrome: successful drug-coated balloon implantation

    Authors

    Keywords

    acute myocardial infarction, antiplatelet therapy, antiphospholipid syndrome

    DOI

    https://doi.org/10.15836/ccar2023.53

    Full Text

    Introduction : Antiphospholipid syndrome is an autoimmune coagulation disorder that is manifests clinically as recurrent venous or arterial thrombosis. In some case thrombocytopenia can be the only manifestation of the syndrome. ( 1 - 3 ) Case report : We present a 43-year-old patient with previously known antiphospholipid syndrome who was admitted to the Coronary Care Unit due to acute myocardial infarction with ST-elevation of the posterolateral location (STEMI). An emergency coronary angiography was performed, which showed thrombotic occlusion of the proximal segment of the circumflex artery. A primary percutaneous coronary intervention was performed, and the target lesion was treated with drug coated balloon (DCB)-Sequent Please Neo 3.0x20 mm. In the control angiography, there is no narrowing. There is a normal TIMI grade 3 flow without any residual thrombus. In the literature, results after treatment of ST-elevation acute coronary syndrome in patients with antiphospholipid syndrome are variable. When PCI is used for STEMI in patient with antiphospholipid syndrome, DCB therapy (although not mentioned in current guidelines) is safe and effective and has shown good clinical effects during a one-year follow-up period. Dual antiplatelet therapy (clopidogrel + aspirin) was started along with warfarin with a target INR >2 (The indication for anticoagulant therapy is the previously known antiphospholipid syndrome). After achieving target INR values, he was discharged and referred to rheumatology and cardiology outpatient clinics for further follow-up. For patients experiencing an acute myocardial infarction of thrombophilic genesis, using thromboaspiration, antiplatelet and anticoagulant medications, as well as applying drug- coated balloons (DCB), can help avoid the placement of a stent and all the complications associated with it. The BASKET SMALL 2 trial has described how this method can provide optimal results.

    Cardiologia Croatica
    Back to search

    ST-elevation acute coronary syndrome with thrombotic occlusion of the proximal segment of the circumflex artery in a patient with antiphospholipid syndrome: successful drug-coated balloon implantation

    Extended Abstract
    Issue3-4
    Published
    Pages53
    PDF via DOIhttps://doi.org/10.15836/ccar2023.53
    acute myocardial infarction
    antiplatelet therapy
    antiphospholipid syndrome

    Authors

    Nikolina Glavinić*ORCIDDubrovnik General Hospital, Dubrovnik, Croatia
    Bruno MihatovićORCIDDubrovnik General Hospital, Dubrovnik, Croatia
    Ana DadićORCIDDubrovnik General Hospital, Dubrovnik, Croatia
    Mihael MatićORCIDDubrovnik General Hospital, Dubrovnik, Croatia

    Full Text

    Introduction : Antiphospholipid syndrome is an autoimmune coagulation disorder that is manifests clinically as recurrent venous or arterial thrombosis. In some case thrombocytopenia can be the only manifestation of the syndrome. ( 1 - 3 ) Case report : We present a 43-year-old patient with previously known antiphospholipid syndrome who was admitted to the Coronary Care Unit due to acute myocardial infarction with ST-elevation of the posterolateral location (STEMI). An emergency coronary angiography was performed, which showed thrombotic occlusion of the proximal segment of the circumflex artery. A primary percutaneous coronary intervention was performed, and the target lesion was treated with drug coated balloon (DCB)-Sequent Please Neo 3.0x20 mm. In the control angiography, there is no narrowing. There is a normal TIMI grade 3 flow without any residual thrombus. In the literature, results after treatment of ST-elevation acute coronary syndrome in patients with antiphospholipid syndrome are variable. When PCI is used for STEMI in patient with antiphospholipid syndrome, DCB therapy (although not mentioned in current guidelines) is safe and effective and has shown good clinical effects during a one-year follow-up period. Dual antiplatelet therapy (clopidogrel + aspirin) was started along with warfarin with a target INR >2 (The indication for anticoagulant therapy is the previously known antiphospholipid syndrome). After achieving target INR values, he was discharged and referred to rheumatology and cardiology outpatient clinics for further follow-up. For patients experiencing an acute myocardial infarction of thrombophilic genesis, using thromboaspiration, antiplatelet and anticoagulant medications, as well as applying drug- coated balloons (DCB), can help avoid the placement of a stent and all the complications associated with it. The BASKET SMALL 2 trial has described how this method can provide optimal results.